David Bruce joined Arstasis as CEO in November 2011 to accelerate the commercial growth phase of the company. Previously he led the successful market penetration and business growth of several product segments in large and small medical device manufacturers. As CEO of EP MedSystems (NASDAQ: EPMD), an electrophysiology equipment and catheter company, he led the company to 30% annual growth over two years culminating in its acquisition by St. Jude Medical. As General Manager of the AcuNav ultrasound catheter business unit within Siemens Medical, he led its market penetration in EP and interventional cardiology procedures resulting in a four-fold increase in revenue during his tenure. Mr. Bruce also served as interim CEO of Patient Safety Technologies, Inc. (NASDAQ: PSTX), redirecting its business model and market positioning leading to sustained growth.

Before his CEO roles, Mr. Bruce was vice president of marketing and business development at Excimer Vision Leasing, a partnership providing laser vision correction systems and consumer marketing to ophthalmologists. Prior to that, he was cardiovascular marketing manager for Acuson Corporation, a leading medical ultrasound vendor.

Mr. Bruce earned a B.S. in mechanical engineering from the University of California, Berkeley, and worked as a product development engineer for five years in semiconductor and computer disc drive industries before earning his MBA from The Wharton School at the University of Pennsylvania.

Mr. Modesitt is a recognized leader in the arteriotomy hemostasis field, having been the primary inventor and designer of the VCD with the fastest revenue ramp to date, the Perclose percutaneous remote suturing device, the Closer. The Closer generated over $100 million in revenue during the first year of sales. In August 2004, Bruce Incorporated Arstasis and transferred into it intellectual property rights for the self-sealing arteriotomy creating access device he invented. From 2004 through present, Bruce has recruited key employees, consultants, suppliers, directors, and investors for Arstasis, and had run the company as its president and CEO.

From 2003 to 2005, Bruce worked as an independent consultant to medical device manufacturers. From 2000 through 2003, Bruce worked at Fogarty Research & Development where, working with Dr. Fogarty, he developed medical devices for vein harvesting, vein stripping, side branch management, remote endarterectomy, abdominal aortic aneurysm repair, and thoracic aortic aneurysm repair. From 1997 through 2000, Bruce worked at Perclose, where he invented the Closer, which caused Abbott Labs to acquire Perclose for $680 million in 1998. The Closer subsequently held 32% of the arteriotomy closure device market. From 1995 through 1997, Bruce worked as an engineer at Progressive Angioplasty Systems (PAS). At PAS, Bruce was the primary inventor and designer of the Paragon™ coronary stent. PAS was sold to US Surgical in August of 1997 for $150 million, primarily because of the Paragon stent. The Paragon stent design remains the basis of many stents on the market today including those produced by Conor Medsystems (now part of Johnson & Johnson). Bruce holds thirty patents and patents pending in the medical device field.

Bruce was awarded a B.S.M.E. degree from Arizona State University in 1982.

In December 2007, Dr. Arrow left his position as the head of medical technology equity research at Lazard Capital Markets to become CFO of Arstasis, Inc. From September 2002 through November 2007, Alex wrote equity research reports evaluating medical device manufacturers, including St. Jude Medical, and an annual overview of emerging medical devices that included vascular closure devices (VCDs). From December 2001 through September 2002 Alex was the publishing medical device analyst at Ladenburg, Thalmann & Co. From September 1999 through December 2001 Alex was the Chief Financial Officer of the Patent & License Exchange, later renamed PLX Systems, Inc., a 64-employee start-up company developing and selling cloud computing software for intellectual property asset management. From August 1996 through September 1999, Alex was the publishing life sciences analyst at Wedbush Morgan Securities. In 1996, he was a surgical resident at the U.C.L.A. Medical Center.

Alex has been individually featured in the New York Times business section and has been profiled or quoted in over 350 print and Internet articles about medical technology companies and market dynamics. He has made guest appearances on television and radio programs including CNBC's Closing Bell Report, Archrivals, The Nightly Business Report with Paul Kangas and National Public Radio's Marketplace.

Alex received a C.F.A. degree from AIMR in 1999. He was awarded an M.D. from Harvard Medical School in 1996, and a BA in Biophysics, magna cum laude, from Cornell University in 1992. He serves on the board of directors of Biolase Technology, Inc. (Nasdaq: BLTI), and Rindex Medical, Inc. (private).